AIM: To evaluate the anti-tumor effect of clobenpropit, which is a specific H<sub>3</sub> antagonist and H<sub>4</sub> agonist, in combination with gemcitabine in a pancreatic cancer cell line.
基金Supported by Korean Society of Internal Medicine Research Fund(2012)the Seoul National University College of Medicine Research Fund(2011)
文摘AIM: To evaluate the anti-tumor effect of clobenpropit, which is a specific H<sub>3</sub> antagonist and H<sub>4</sub> agonist, in combination with gemcitabine in a pancreatic cancer cell line.